Tirzepatide emerges a groundbreaking therapeutic agent for individuals battling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://lulufqus553335.qowap.com/99591991/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist